April 7, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the European Patent Office.
Read morePress releases
All releases
InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe
07 April 2021
- Other press release
InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis
30 March 2021
- Other press release
March 30, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod f...
Read moreInDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting
15 March 2021
- Other press release
March 15, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced changes in the composition of the Nomination Committee for the 2021 Annual General Meeting due to changes in the ownership structure of the company.
Read moreInDex Pharmaceuticals updates shareholders list
12 March 2021
- Other press release
March 12, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021.
Read moreInDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar
10 March 2021
- Other press release
March 10, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Barclays Global Healthcare Conference on Thursday March 11, 2021 and at Carnegie Nordic Virtual Healthcare Seminar on Friday March 12, 2021, both at 13:30 CET.
Read moreInDex Pharmaceuticals Holding AB (publ) year-end report 2020
25 February 2021
- Regulatory press release
Financing secured for phase III development of cobitolimod
Read moreInDex Pharmaceuticals’ rights issue is oversubscribed
09 February 2021
- Regulatory press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE...
Read moreInDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue
21 January 2021
- Regulatory press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. 21 January 2021 – The b...
Read moreThe board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533
14 January 2021
- Regulatory press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. 14 January 2021 – The b...
Read moreBulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
12 January 2021
- Regulatory press release
12 January 2021 – The Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) was held on 12 January 2021 at the offices of Setterwalls Advokatbyrå at Sturegatan 10, Stockholm. Attendance at the meeting was solely possible via postal voting. The following resolutions were passed at th...
Read more